CN104302183B - 飞燕草色素对抗金黄色葡萄球菌的应用 - Google Patents
飞燕草色素对抗金黄色葡萄球菌的应用 Download PDFInfo
- Publication number
- CN104302183B CN104302183B CN201380018669.7A CN201380018669A CN104302183B CN 104302183 B CN104302183 B CN 104302183B CN 201380018669 A CN201380018669 A CN 201380018669A CN 104302183 B CN104302183 B CN 104302183B
- Authority
- CN
- China
- Prior art keywords
- delphinidin
- complex
- antibiotic
- individuality
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000007242 delphinidin Nutrition 0.000 title claims abstract description 70
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 title claims abstract description 67
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 title claims abstract 22
- 230000000941 anti-staphylcoccal effect Effects 0.000 title description 2
- 230000003115 biocidal effect Effects 0.000 claims abstract description 38
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 29
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 20
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 39
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 229920000858 Cyclodextrin Polymers 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 18
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004964 sulfoalkyl group Chemical group 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000001033 ether group Chemical group 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229940126575 aminoglycoside Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 235000013622 meat product Nutrition 0.000 claims description 3
- 244000144977 poultry Species 0.000 claims description 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 claims description 2
- 206010007247 Carbuncle Diseases 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 206010017553 Furuncle Diseases 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 201000001177 Pyomyositis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 2
- 229960003644 aztreonam Drugs 0.000 claims description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 206010040872 skin infection Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical group OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 8
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 229930014669 anthocyanidin Natural products 0.000 description 23
- 235000008758 anthocyanidins Nutrition 0.000 description 23
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- -1 injecting Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- 206010041925 Staphylococcal infections Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- KQIKOUUKQBTQBE-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KQIKOUUKQBTQBE-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 244000215562 Heliotropium arborescens Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- KNEPVLLGXUSFJS-UHFFFAOYSA-N Tauranin Natural products C=C1CCC2C(C)(C)CCCC2(C)C1CC1=C(O)C(=O)C(CO)=CC1=O KNEPVLLGXUSFJS-UHFFFAOYSA-N 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 108010080591 aurantin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Chemical group 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical class NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004412 visual outcomes Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
- A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明涉及飞燕草色素或者其盐类物质的应用,所述飞燕草色素或者其盐类物质针对如下细菌:对抗生素显耐药性的金黄色葡萄球菌以及对抗生素显低敏感性的金黄色葡萄球菌,并可以至少部分地中和所述细菌。此外,本发明还涉及一种使用飞燕草色素或者其盐类物质治疗个体的方法。
Description
技术领域
本发明涉及花青素类飞燕草素色和其盐类物质的应用,用于对抗对抗生素显耐药性的细菌和对抗生素显低敏感性的细菌。
背景技术
花青素是一种细胞色素染料,存在于多数的高陆生植物中。花青素中不含糖分(糖苷配基)并且与含糖花色苷(配糖体)密切相关,两者均归入花青素类的通用标题。花青素是一种具有抗氧化特性的染料。
对抗生素显耐药性的细菌和对抗生素显低敏感性的细菌常常出现在经常使用抗生素的地方。对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌属于最危险的医院获得性病原体,即医院感染,这种细菌不仅可以通过皮肤和粘膜传染,而且可以通过受感染的医疗器械或者食品传染。
特别是由于在治疗细菌感染性疾病中越来越多地使用广谱抗生素,发现越来越多的抗多种抗生素的细菌,因此在治疗这些细菌感染的病人和动物的过程中,不再有有效的抗生素。对抗生素显耐药性的细菌可以在人类或者动物中造成严重的全身感染。特别是对于免疫抑制的病人而言尤为严重。
发明内容
本发明的目的在于提出一种有效的试剂,用于预防和治疗细菌感染性疾病。
此外,本发明的目的还在于提出一种有效的试剂,用于对抗对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌。
本发明用来达成上述目的的解决方案是权利要求1中提到的飞燕草素色和其盐类物质的应用,权利要求5中提到的方法和权利要求11和12中提到的应用。本发明的优选实施例也在从属权利要求中公开。
首先,对本发明中提到的几个概念进行说明。
“抗生素”是指用于治疗细菌感染性疾病的药物。抗生素具体包含β-内酰胺类抗生素(包括青霉素,头孢菌素,碳青霉烯类及单环内酰胺类),喹诺酮类,四环素类,氨基糖苷类,红霉素,磺胺类和万古霉素。“对抗生素显耐药性的细菌”和“对抗生素显低敏感性的细菌”是指所述细菌至少对一种抗生素具有抗药性和/或对至少一种抗生素具有降低的敏感性。多重耐药性的金黄色葡萄球菌菌株对现在市场上存有的β-内酰胺类抗生素都具有抗药性并且对其他多数抗生素类药物(即喹诺酮类,四环素,氨基糖苷类抗生素,红霉素和磺胺类)具有抗药性,本领域本共同地被称作“MRSA”(Multi-resistenter Staphyloccocusaureus或Methicillin-resistenter Staphyloccocus aureus)。通常情况下,针对MRSA的疗法是使用备用抗生素万古霉素,但是对万古霉素具有耐药性的细菌也越来越多(“VRSA”–vancomycin-resistant Staphylococcus aureus),因此迫切需要一种替代药物来治疗细菌感染性疾病。
根据本发明,使用如权利要求1至7中任一项所述的组合物或者复合物或者如权利要求8中所述的水溶液或者固体治疗被如下细菌感染的个体或者个人:对抗生素显耐药性的金黄色葡萄球菌以及对抗生素显敏感性的金黄色葡萄球菌。上述治疗过程的目的在于至少部分地去中和所述细菌。而所述中和过程又包含多种类型,例如抑菌中和,杀菌中和以及抑菌-杀菌的混合中和。概念“包含至少一种花青素的组合物或者复合物”指包含一种花青素但无其它组份的组合物或者复合物。
对于卫生行业的应用而言,本发明中如权利要求1至7中任一项所述的组合物或者复合物或者如权利要求8中所述的水溶液或者固体被用于预防和治疗被如下细菌感染的人类或者动物:对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌。细菌感染具体造成具有如:皮肤感染包括疔疮和痈肿,化脓性肌炎,肺炎,心内膜炎,毒性休克症候群,败血症和乳腺炎症状的疾病。特别是对于免疫抑制的病人而言,对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌可以造成严重的全身感染。
对于食品,饲料和消毒行业而言,概念“个体”包含非活体动物、医疗应用、食品加工和军事领域的装置和/或者设备和/或者器材和/或者器具,防护器材,家用物体,建筑设备和建筑工程。特别的是,“非活体动物”指被杀死的或屠宰的动物或者这些动物的一部分,例如,牛的身体,或者牛身体的一部分,猪的身体,或者猪身体的一部分,家禽的身体,或者家禽身体的一部分,水生动物的身体,或者水生动物身体的一部分。特别的是,“个体”可指一种食品或者饲料,例如一种肉制品,一种加工过的肉制品,一种乳制品,蔬菜以及它们的一部分,水果以及它们的一部分。
在本发明中,“中和”指破坏,化解(溶解),去活(即失去感染的潜在风险)或防止病原体的繁殖或者病原体介导的生物膜的形成,特别的是对于对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌。
本发明所述的组合物或者复合物可以以胶体、敷料、膏药、贴剂或类似形式通过喷雾应用、搽粉、注射、涂膜对疑似感染的区域进行给药或应用。在针对人类或者动物的治疗过程中,可以借助临床图像将本发明所述的组合物或者复合物置于全身或者局部。剂型和给药所对应的技术是现有技术中公知的,例如“雷明顿药物科学”(Mack Publishing Co,Easton Pa.)。例如本发明的所述组合物或者复合物可借助一个医学上可接受的载体(例如生理盐水)向一对象静脉注射给药。合适的注射剂型是在水溶液中的剂型,优选的是,在生理上可接受的缓冲液中(例如汉克斯溶液、林格溶液或者生理缓冲盐水)。对于肠胃外给药(包括静脉内给药、皮下给药、肌肉内给药和腹膜内给药)也同样需要用到水性或者油性的溶液或者固体制剂。
“生物膜”是微生物(如细菌)的一个集合,嵌入在一个外表面上由微生物产生的胞外多糖基质或者蛋白基质。生物膜中的细菌结构显著地提高了人体对各种影响的抵抗力。由细菌在牙齿、牙龈、泌尿道、消化道或者医疗设备(如导管和假体)上导致的生物膜常常导致严重的感染(Costerton et al.,Annu Rev.Microbiol1995;49:711-45)。
“盐类物质”或者“医学上可接受的盐类物质”指与本发明相关度从医学角度而言可接受的盐类物质,该盐类物质可以在给药之后释放有效的药物的活性成分或者其活性代谢物。本发明所述组合物或者复合物的盐类物质可以是有机或者无机的酸和碱。
所述花青素使用时可以是“纯的”或者“纯化的”,即所述花青素中不需要的组份已经被去除。
所述花青素具有如下基本结构:
其取代基由如下物质组成:氢原子,羟基基团和甲氧基基团。
所述环糊精为由α-1,4-糖苷连接的葡萄糖分子组成的环状低聚糖,依照本发明可与花青素复合。所述β-环糊精具有七个葡萄糖单元。在一个磺烷基醚-β-环糊精中,葡萄糖的羟基基团被醚化在磺烷基醇中。根据本发明,通常β-环糊精的21个羟基基团中只有一部分被醚化。对于本领域的技术人员而言,所述磺烷基醚环糊精的制备法是众所周知的,例如在US5,134,127和WO2009/134347A2中对其进行了描述。
在现有技术中,磺烷基醚基团被用来提高环糊精的亲水性或者水溶性。本发明已经意识到:磺烷基醚基团对于提高由花青素和相应的被取代的β-环糊精组成的复合物的稳定性具有特定作用,从而大大地改善易氧化的花青素的储存稳定性、以及可配制性。本发明的复合物即可以配制成储存稳定性好的水溶液或固体,下文中将更加详细地加以描述。
根据本发明,特别优选的是,与磺丁基醚-β-环糊精(SBE-β-CD)的复合。在此,需要申明的是本发明并不受其限制的部分如下:带负电荷的磺单元与带正电荷花青素之间存在静电作用,在烷基基团中正丁基团具有最优的长度,从而实现空间上相应的相互作用。
优选的是,所述环糊精与所述磺烷基醚基团的取代度在3-8的范围之间,更优选为4-8,更优选为5-8,更优选为6-7。。例如,在业已公开的专利申请WO2009/134347A2中描述了一种平均取代度在6至7范围之间的合适的磺烷基醚-β-环糊精,这种磺烷基醚-β-环糊精在市面上商品名为当然,取代度在4至5的范围之间的环糊精也是可用的,例如取代度为4.2的环糊精。
本发明的所述的纯的、盐形式的、或复合物形式的花青素优选自如下物质:橙苷色素、矢车菊色素、飞燕草色素、欧天芥菜色素、四羟花色素、天竺葵色素、锦葵色素、芍药色素、碧东茄色素和松香色素。其化学结构中的相应的取代基如下所示:
在本发明中,特别优选的是飞燕草色素。
进一步地,本发明涉及一种本发明的组合物或者本发明的复合物的水溶液。
进一步地,本发明涉及一种制备这种复合物以及相应的水溶液的方法,包含如下步骤:
a)制备磺烷基醚-β-环糊精的水溶液,
b)将花青素加入水溶液并混合,从而制得复合物。
优选的是,在步骤a)中制备的溶液中所述磺烷基醚-β-环糊精的质量百分比在5至10的范围之间。特别优选的是,在本发明的范围之间,花青素(特别的是飞燕草色素)加入水溶液过程和之后,特别优选的是,花青素(特别的是飞燕草色素)加入水溶液之前,水溶液pH值等于或者小于7,优选的是,其pH值等于或者小于6,进一步优选的是,其pH值等于或者小于5,进一步优选的是,其pH值等于或者小于4至5。在上述pH值的情况下,所述水溶液中的所述复合物的浓度可以更高。
所述花青素的浓度(以氯化物计)大于或者等于0.5mg/ml,优选的是,所述花青素的浓度大于或者等于1.0mg/ml,进一步优选的是,所述花青素的浓度大于或者等于1.5mg/ml,进一步优选的是,所述花青素的浓度大于或者等于2.0mg/ml。在本发明的一个优选实施形式中,所述花青素的浓度大于或者等于2.0mg/ml,其水溶液的pH值在4至5的范围之间。
在本发明的范围内,所述水溶液中各成分通过搅拌进行混合,优选的是,混合过程在避光的条件下(为了避免由光诱导的氧化)持续2至20个小时。
进一步地,本发明还涉及一种包括本发明的复合物的固体,所述固体通过除去本发明的水溶液中的溶剂而获得。优选的是,通过冷冻干燥除去本发明的水溶液的溶剂。不管是本发明的水溶液还是本发明的固体,都具有很好的储存稳定性。
具体实施例
下面参照附图结合但并不限于下文的具体实施例对本发明进行进一步的描述。
I.由花青素飞燕草色素和环糊精制备一种复合物
1.所用的材料
下述材料被用在环糊精中:
α-CD | ID No:CYL-2322 |
β-CD | ID No:CYL-3190 |
γ-CD | ID No:CYL-2323 |
(2-羟丙基)-β-CD | ID No:L-043/07 |
磺丁基醚-β-CD | ID No:47K010111 |
飞燕草色素氯化物由Extrasynthese合成。
2.确定飞燕草色素的含量
反相HPLC技术被用来确定含有飞燕草色素的混合物中飞燕草色素的含量,在此
需要用到如下反应物:
纯净水
色谱仪所需的甲醇
甲酸p.a.
1M盐酸滴定溶液
所使用的柱为Waters X BridgeTM C18,35μl,150mmx4.6mm。
其中流动相如下:
A相:水950ml,甲醇50ml,甲酸10ml
B相:水50ml,甲醇950ml,甲酸10ml
所使用的梯度洗脱程序如下:
时间(分钟) | B相百分比 |
0 | 0 |
5 | 0 |
25 | 60 |
30 | 100 |
停止采集时间:35分钟
后运行时间:8分钟
流动速率:1ml/min
进样体积:20μl
柱温:30℃+/-2℃
紫外-可见光检测器:530μm用于测定,275μm用于检测杂质
积分仪:面积
溶液和样品的制备:
稀释溶液1:100ml甲醇和2.6ml1M的盐酸混合溶液
稀释溶液2:100ml40%的甲醇和2.6ml1M的盐酸混合溶液
校定溶液:飞燕草色素的基准溶液按照如下方式进行制备:称10mg飞燕草色素氯化物放入10ml的烧杯中,并溶解到稀释溶液1。溶解之后,使用稀释液2再稀释10倍左右,从而制备出浓度约为0.1mg/ml的溶液。
对照校定溶液将以相同的方式制备。随后校定溶液必须立刻通过HPLC进行分析,因为飞燕草色素氯化物在溶液中不稳定。
制备检测溶液:
本发明制备的固体的飞燕草色素含量按照如下方案进行确定(制备方法见下文):称取大约50mg的所述混合物加入10ml的烧杯中。随后将其溶解到稀释溶液2中,并稀释至其飞燕草色素浓度达到0.1mg/ml左右。
样品中的飞燕草色素的含量按照如下方案进行确定:在安捷伦化学站工作站软件的辅助下使用外部标准的校定程序进行计算。
实施例1
飞燕草色素与磺丁基醚-β-环糊精(SBE-β-CD)的复合
在本实施例中,飞燕草色素与不同的环糊精混合,从而观察复合物在水溶液中的溶解性。
通常情况下,制备的中性水溶液中,各个环糊精的重量百分比为10。而加入β-CD的水溶液中,由于其较差的溶解性,环糊精的重量百分比仅为2。
每5ml环糊精水溶液与相应的纯净水被放入玻璃烧杯中。随后,加入过量的飞燕草色素氯化物。其中,所述过量的燕草色素氯化物的具体用量如下:α-,β-,γ-环糊精溶液中为10mg,HPBCD(2羟丙基-β-环糊精)和SBE-β-CD中为15mg。
将悬浮液在30℃的避光条件下搅拌20个小时。随后,使用孔径为0.22μm的过滤膜对悬浮液进行过滤。
表格1所示为所能达到的溶解度。
环糊精 | 环糊精浓度 | 飞燕草色素氯化物 |
- | 0 | 0.07mg/ml |
α-CD | 10% | 0.14mg/ml |
β-CD | 2% | 0.05mg/ml |
γ-CD | 10% | 0.21mg/ml |
HPBCD | 10% | 0.19mg/ml |
SBE-β-CD | 10% | 0.66mg/ml |
从中可以看出,与其它环糊精相比,带有SBE-β-CD的复合物和生成物具有更高的溶解性。
实施例2
pH值的影响
在本实施例中,将研究pH值对水溶液中飞燕草色素-SBE-β-CD溶解性的影响。根据实施例1中所述的方法制备SBE-β-CD水溶液,然后使用1M的盐酸将该溶液调配成表格2中所示的酸性pH值。随后,根据实施例1中所述的方法将飞燕草色素氯化物加入到水溶液中并进行进一步的处理,其唯一的区别在于:限制搅拌时间至2.5个小时。最终的结果如表格2所示。
pH | 飞燕草色素氯化物 |
6.0 | 0.60mg/ml |
4.8 | 2.12mg/ml |
4.1 | 2.03mg/ml |
从中可以看出,pH值在4至5的范围之间的飞燕草色素复合物的溶解性大概是中性pH值的飞燕草色素复合物的溶解性的3倍左右。
实施例3
制备本发明的固体
在本实施例中,将本发明的复合物制配成固体。为了易于比较,将准备飞燕草色素/HPBCD复合物以及飞燕草色素/淀粉固体剂型。
实施例3.1
飞燕草色素/SBE-β-CD
5gSBE-β-CD溶解至40ml蒸馏水中,得到澄清溶液。借助1M的盐酸将该溶液的pH值调整至4.8。随后加入0.11g飞燕草色素氯化物,并在27℃的避光条件下搅拌2个小时。使用孔径为0.45μm的硝酸纤维素过滤膜对均匀的液体进行真空过滤。随后溶液将被冷冻并在温度为-48℃、压强约为10.3Pa(77mTorr)的条件下冷冻干燥。再将冻干物进行碾磨,然后通过网格为0.3mm的筛子进行筛选。
实施例3.2
飞燕草色素/HPBCD
按照实施例3.1所述的方式制备样品,其中在过滤过程中被过滤的材料更多,这就意味着,与实施例3.1相比,本实施例的增溶作用被显著地降低。
实施例3.3
飞燕草色素/淀粉剂型
5g淀粉悬浮在40ml蒸馏水中。由此可得到一种白色的悬浮液。借助1M的盐酸将该溶液的pH值调整至4.6。随后加入0.11g飞燕草色素氯化物,并在27℃的避光条件下搅拌2个小时。所得均匀的溶液使用实施例3.1中相同的方法进行冷冻干燥、碾磨和筛选。
实施例3.1为本发明的实施形式,而实施例3.2和3.3为对比实施例。
实施例4
稳定性试验
根据实施例3.1至3.3制备的固体被储存在如下环境中:
-在室温下,存放在褐色的、螺旋拧紧的玻璃容器中储存8天
-随后在室温、避光条件下,存放在具有氧气气氛的玻璃容器中22天。
上文所述的最后22天将在容量为20ml的玻璃小瓶中进行。每个玻璃小瓶中放入250mg已经储存了8天的样品,再使用一个橡胶瓶塞将玻璃小瓶盖住并密封。借助两个注射针头将氧气从玻璃小瓶的顶部注入。随后,将样品储存在避光的条件下。
上述固体的飞燕草色素含量(以飞燕草色素氯化物计,以质量百分比表示)将通过上述HPLC方法来确定。结果如表3所示。
上述结果显示:本发明中制备的飞燕草色素复合物,在纯氧气气氛中具有更高的稳定性,从而具有更好的储存稳定性。进一步地,该复合物在水溶液中具有很好的溶解性,特别的是在微酸性溶液中具有很好的溶解性,从而使飞燕草色素依照本发明可以被制配成各种形式。本发明固体的稳定性与淀粉剂型(实施例3.3)具有相似性质,但此对比例不能被配置于水溶液中。
实施例5
水溶液中的稳定性试验
与上文所述类似的反向HPLC技术被用来确定含有飞燕草色素的溶液中飞燕草色素的含量,在此需要用到如下试剂:
纯净水
色谱仪所需的甲醇
甲酸p.a.
1M盐酸滴定溶液
所使用的柱为Waters X BridgeTM C18,35μl,150mmx4.6mm。
其中流动相如下:
A相:水700ml,甲醇230ml,甲酸10ml
B相:水50ml,甲醇950ml,甲酸10ml
所使用的梯度洗脱程序如下:
时间(分钟) | B相百分比 |
0 | 0 |
5 | 0 |
25 | 20 |
30 | 100 |
停止采集时间:25分钟
后运行时间:8分钟
流动速率:1ml/min
进样体积:20μl
柱温:30℃+/-2℃
紫外-可见光检测器:530μm用于测定,275μm用于检测杂质
积分仪:面积
溶液和样品的制备:
稀释溶液1:100ml甲醇和2.6ml1M的盐酸混合溶液
稀释溶液2:100ml50%的甲醇和2.6ml1M的盐酸混合溶液
校定溶液:飞燕草色素的基准溶液按照如下方式进行制备:称10mg飞燕草色素氯化物放入10ml的烧杯中,并溶解到稀释溶液1。溶解之后,使用稀释液2再稀释10倍左右,从而制备出浓度约为0.1mg/ml的溶液。
对照校定溶液将以相同的方式制备。随后校定溶液必须立刻通过HPLC进行分析,因为飞燕草色素氯化物在溶液中不稳定。
制备检测溶液:
为了确定一种本发明的水溶液中飞燕草色素的含量,实施例3.1中的飞燕草色素/SBE-β-CD(本发明)和飞燕草色素(对比实施例)被溶解在0.9%的NaCl溶液中,直至起始浓度(飞燕草色素的浓度)达到1.584mg/ml(本发明的实施例)以及0.0216mg/ml(对比实施例)。上述溶液在室温条件下制备,随后在37℃的避光条件下储存在密封的小瓶内。
结果1、2、3、4个小时后,就可以确定飞燕草色素的含量。下表格给出了所得含量,为上述起始浓度的百分比。
时间(小时) | 未复合的飞燕草色素 | 飞燕草色素/SBE-β-CD |
0 | 100% | 100% |
1 | 8.3% | 80.7% |
2 | 6.5% | 74.5% |
3 | 5.6% | 64.7% |
4 | 5.1% | 62.8% |
样品中的飞燕草色素的含量按照如下方案进行确定:在安捷伦化学站工作站软件的辅助下使用外部标准的校定程序进行计算。
II.花青素飞燕草色素对细菌的影响
1.实验菌株和试验装置
实验菌株如下:
-绿脓假单胞菌ATCC9027,生物膜-阳性临床分离自一外耳感染(参考菌株);
-肺炎克雷伯菌ATCC700603,生物膜-阳性临床分离自一ESBL+(超光谱β内酰胺酶)病人的尿液中(参考菌株);
-金黄色葡萄球菌MSSA2318,生物膜-阳性临床分离自2009/04/22(维尔茨堡大学医学院,医疗诊所和综合诊所I,加护病房)的气管分泌物;
-金黄色葡萄球菌MSSA2855,生物膜-阳性临床分离自2009/04/22(维尔茨堡大学医学院,医疗诊所和综合诊所I,加护病房)的血培养中;
-金黄色葡萄球菌MRSA1155,生物膜-阳性临床分离自2009/04/27(维尔茨堡大学医学院,泌尿科,B站)的腹腔涂片中。
如图1所示,上述菌株的生物膜形成非常的明显,因此特别适用于本发明的组合物对细菌的影响试验。
图1为在两个独立的实验中各种菌株(绿脓假单胞菌和肺炎克雷伯菌以及MRSA和MSSA菌株)48小时后生物膜静态形成的结果。生物膜的生长情况以及对其的分析将借助结晶紫实验(根据Current Protocols in Microbiology1B.1.2-1B.1.4”MICROTITER PLATEBIOFIM ASSAY”中的基本协议1[2011年8月在威利网上图书馆网上公布(wileyonlinelibrary.com)DO:10.1002/9780471729259,mc01b01s22])在一个静态模型中完成。
2.活性成分分析
飞燕草色素对细菌成长和细菌对生物膜形成的影响的试验借助如下几个步骤进行:
a)视觉上评估细菌的成长状况(静态模型),
b)活力实验(血琼脂平板上的条文)
c)借助第一部分中提到的结晶紫实验在静态模型中分析生物膜
首先,1x106细菌/孔与100μL带有酚红的RPMI-1640细胞培养基放入一个96-孔-聚苯乙烯-细胞培养皿中,其中酚红作为pH值的指标(并由此作为细菌生长情况的间接指标),无菌的RPMI-1640作为对照样。随后将事先准备好的稀释液中的飞燕草色素加入其中,将细胞培养皿在37℃的环境下培育48个小时,其目视结果如图2所示。随着细菌的成长幅度,颜色从(酚)红色变成黄色。
如图3(绿脓假单胞菌ATCC9027)、4(肺炎克雷伯菌ATCC700603)、5(MRSA2318)、6(MRSA2855)、7(MSSA1155)所示为培养皿中细菌的涂片。在琼脂平板的涂片中“ST_26.1.11”和“ST_28.1.1”分别指重复实验的涂片日期。
使用同样的实验装置,借助第一部分中提到的结晶紫实验可以分析生物膜的状况。如图8所示为48小时培育结果和结晶紫实验后的结果,图9至图13所示分别为每个菌株在各个飞燕草色素浓度下光密度的测定结果(图9:绿脓假单胞菌ATCC9027,图10肺炎克雷伯菌ATCC700603,图11 MRSA2318,图12 MRSA2855,图13 MSSA1155)。
上述试验结果如下:
-飞燕草色素对革兰氏阳性细菌(绿脓假单胞菌和肺炎克雷伯菌)的生长和生物膜形成没有抑制作用。对肺炎克雷伯菌甚至有刺激作用。
-相反地,飞燕草色素对金黄色葡萄球菌(不管是MSSA还是MRSA)的生长和生物膜形成有抑制作用。这种抑制作用随着剂量的增加而变大。
Claims (16)
1.飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物的运用,治疗感染了如下细菌的无生命的个体:对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌。
2.如权利要求1中所述的运用,其特征在于,对所述个体的治疗可以中和所述细菌,即破坏、化解、去活和防止金黄色葡萄球菌的繁殖或者防止金黄色葡萄球菌介导的生物膜的形成。
3.如权利要求1中所述的运用,其特征在于,所述抗生素选自:
-β-内酰胺类抗生素,包括青霉素,头孢菌素,碳青霉烯类及单环内酰胺,
-喹诺酮类
-四环素类,
-氨基糖苷类,
-红霉素,
-磺胺类,和
-万古霉素。
4.如权利要求1、2或者3中所述的运用,其特征在于,所述飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物包含在一种水溶液或者一种固体中。
5.如权利要求4中所述的运用,其特征在于,所述水溶液或者所述固体为材料或者一种冲洗液的附加物。
6.用于治疗一种个体的方法,其中所述个体不是活体动物,包含:
-制备
-飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物或者一种包含飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物的水溶液或者固体
-一种非活体个体,该个体疑似被如下细菌感染:对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌
-在如下条件下使用飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物或者水溶液或者固体治疗个体:疑似被细菌感染的个体中,细菌至少被部分地被破坏、化解、去活,或防止金黄色葡萄球菌介导的生物膜的形成。
7.如权利要求6中所述的方法,其特征在于,所述个体为一种动物的身体或者动物身体的一部分。
8.如权利要求7中所述的方法,其特征在于,所述动物的身体或者动物身体的一部分为:
-牛的身体,或者牛身体的一部分,
-猪的身体,或者猪身体的一部分,
-家禽的身体,或者家禽身体的一部分,
-水生动物的身体,或者水生动物身体的一部分。
9.如权利要求6中所述的方法,其特征在于,所述个体为一种食品和/或者饲料。
10.如权利要求9中所述的方法,其特征在于,所述个体为一种食品和/或者饲料,
其中所述食品和/或者饲料为:
-一种肉制品,
-一种加工过的肉制品,
-一种乳制品,
-蔬菜以及它们的一部分,
-水果以及它们的一部分。
11.如权利要求6中所述的方法,其特征在于,所述个体为:
-用于如下领域的装置和/或者设备和/或者器材和/或者器具
-医疗应用
-食品加工
-军事
-防护器材,
-家用物体,
-建筑设备,和
-建筑工程。
12.飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物或者包含飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物的水溶液或者固体在治疗被如下细菌感染的无生命的个体中的运用:对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌。
13.飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物或者包含飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物的水溶液或者固体的运用,用于制备用于治疗或者预防被如下细菌感染的人类或者动物的药物:对抗生素显耐药性的金黄色葡萄球菌和对抗生素显低敏感性的金黄色葡萄球菌。
14.如权利要求13中所述的飞燕草色素或者其盐类物质或者包含飞燕草色素的复合物或者水溶液或者固体的运用,其特征在于,细菌感染造成具有如下症状的疾病:
-皮肤感染包括疔疮和痈肿,
-化脓性肌炎,
-肺炎,
-心内膜炎,
-毒性休克症候群,
-败血症,和
-乳腺炎。
15.如权利要求1-5中任一项所述的运用,权利要求6-11中任一项所述的方法或者权利要求12-14中任一项所述的运用,其特征在于,所述包含飞燕草色素的复合物
-包含磺烷基醚-β-环糊精,和
-所述环糊精与所述磺烷基醚基团的取代度在3至8的范围之间。
16.如权利要求1-5中任一项所述的运用,权利要求6-11中任一项所述的方法或者权利要求12-14中任一项所述的运用,其特征在于,所述包含飞燕草色素的复合物
-包含磺丁基醚-β-环糊精,和
-所述环糊精与所述磺丁基醚基团的取代度在3至8的范围之间。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12002352 | 2012-03-30 | ||
EP12002352.8 | 2012-03-30 | ||
PCT/EP2013/056725 WO2013144306A1 (de) | 2012-03-30 | 2013-03-28 | Verwendung von delphinidin gegen staphylococcus aureus |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104302183A CN104302183A (zh) | 2015-01-21 |
CN104302183B true CN104302183B (zh) | 2017-03-01 |
Family
ID=47998469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380018669.7A Active CN104302183B (zh) | 2012-03-30 | 2013-03-28 | 飞燕草色素对抗金黄色葡萄球菌的应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150051273A1 (zh) |
EP (1) | EP2854553B1 (zh) |
JP (2) | JP6193970B2 (zh) |
KR (1) | KR101905239B1 (zh) |
CN (1) | CN104302183B (zh) |
CA (1) | CA2869057C (zh) |
ES (1) | ES2620080T3 (zh) |
HK (1) | HK1206203A1 (zh) |
WO (2) | WO2013144306A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2908829A1 (de) * | 2012-10-17 | 2015-08-26 | SapioTec GmbH | Anthocyanidin-komplex zur behandlung von multiplem myelom |
EP2919791B1 (de) | 2012-11-15 | 2017-03-22 | SapioTec GmbH | Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff |
KR102164174B1 (ko) | 2012-12-11 | 2020-10-12 | 자피오텍 게엠베하 | 흑색종 세포를 퇴치하기 위한 델피니딘 |
EP2913366A1 (de) * | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Anthocyanidin-Komplex |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0390496A1 (en) * | 1989-03-28 | 1990-10-03 | IDB HOLDING S.p.A. | Intermediates useful for the synthesis of delphinidin chloride |
JP2003171274A (ja) * | 2001-12-07 | 2003-06-17 | Tomihiko Higuchi | 薬剤耐性菌感染症治療のための医薬組成物および消毒剤 |
CN102319369A (zh) * | 2011-09-20 | 2012-01-18 | 东莞宏力生物科技有限公司 | 花青素提取物和玉米须提取物的混合液在制备抑菌药物上的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JP2000212092A (ja) * | 1999-01-27 | 2000-08-02 | Yanai Yoshiaki | 抗ウイルス・抗菌剤 |
JP2004238336A (ja) * | 2003-02-07 | 2004-08-26 | Sanei Gen Ffi Inc | 水易溶性包接フラボノイド類の製造方法 |
CN1317961C (zh) * | 2004-03-25 | 2007-05-30 | 吴朝琴 | 冻干草莓加工工艺 |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
WO2010011605A2 (en) * | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
WO2010141760A2 (en) * | 2009-06-05 | 2010-12-09 | The Regents Of The University Of Colorado, A Body Corporate | Antimicrobial peptides |
EP2344154B1 (en) * | 2009-10-21 | 2016-12-07 | Maqui New Life S.A. | Compositions that include anthocyanidins and methods of use |
EP3513660B1 (en) * | 2010-03-13 | 2024-08-21 | Eastpond Laboratories Limited | Fat-binding compositions |
DK2831122T3 (da) * | 2012-03-30 | 2016-05-17 | Sapiotec Gmbh | Anthocyanidin-kompleks |
-
2013
- 2013-03-28 US US14/389,492 patent/US20150051273A1/en not_active Abandoned
- 2013-03-28 WO PCT/EP2013/056725 patent/WO2013144306A1/de active Application Filing
- 2013-03-28 ES ES13719034.4T patent/ES2620080T3/es active Active
- 2013-03-28 EP EP13719034.4A patent/EP2854553B1/de active Active
- 2013-03-28 KR KR1020147030100A patent/KR101905239B1/ko active IP Right Grant
- 2013-03-28 CA CA2869057A patent/CA2869057C/en active Active
- 2013-03-28 JP JP2015502359A patent/JP6193970B2/ja active Active
- 2013-03-28 WO PCT/EP2013/056722 patent/WO2013144303A1/de active Application Filing
- 2013-03-28 CN CN201380018669.7A patent/CN104302183B/zh active Active
-
2015
- 2015-07-21 HK HK15106932.1A patent/HK1206203A1/zh unknown
-
2017
- 2017-05-09 JP JP2017092774A patent/JP2017197540A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0390496A1 (en) * | 1989-03-28 | 1990-10-03 | IDB HOLDING S.p.A. | Intermediates useful for the synthesis of delphinidin chloride |
JP2003171274A (ja) * | 2001-12-07 | 2003-06-17 | Tomihiko Higuchi | 薬剤耐性菌感染症治療のための医薬組成物および消毒剤 |
CN102319369A (zh) * | 2011-09-20 | 2012-01-18 | 东莞宏力生物科技有限公司 | 花青素提取物和玉米须提取物的混合液在制备抑菌药物上的用途 |
Non-Patent Citations (5)
Title |
---|
Antibacterial and Antifungal Activities of Punica Granatum Peel Extracts Against Oral Pathogens.;Sh. Abdollahzadeh 等;《Journal of Dentistry》;20110331;第8卷(第1期);1-6 * |
Delphinidin, an Anthocyanidin in Pigmented Fruits and Vegetables, Protects Human HaCaT Keratinocytes and Mouse Skin Against UVB-Mediated Oxidative Stress and Apoptosis.;Farrukh Afaq 等;《Journal of Investigative Dermatology》;20060810;第127卷(第1期);222-232 * |
Efficiency of Pomegranate Peel Extract as Antimicrobial, Antioxidant and Protective Agents.;M.I. Ibrahium;《World Journal of Agricultural Sciences》;20100731;第6卷(第4期);338-344 * |
IDENTIFIKASI SENYAWA FENOL DAN DELFINIDIN PADA KEMBANG TELANG (Clitoria ternatea L.) SERTA UJI EFEKTIVITASNYA TERHADAP Staphylococcus aureus PENYEBAB RADANG MATA.;Tiurlan F.Hutajalu 等;《Journal of Agro-Based Industry》;20081231;第25卷(第2期);摘要 * |
Tannins and other phytochemical of the Samanaea saman pods and their antimicrobial activities.;Pius O. Ukoha 等;《African Journal of Pure and Applied Chemistry》;20110831;第5卷(第8期);237-244 * |
Also Published As
Publication number | Publication date |
---|---|
JP2015518466A (ja) | 2015-07-02 |
KR101905239B1 (ko) | 2018-10-05 |
JP2017197540A (ja) | 2017-11-02 |
WO2013144303A1 (de) | 2013-10-03 |
EP2854553B1 (de) | 2016-12-21 |
ES2620080T3 (es) | 2017-06-27 |
KR20150003222A (ko) | 2015-01-08 |
CN104302183A (zh) | 2015-01-21 |
WO2013144306A1 (de) | 2013-10-03 |
EP2854553A1 (de) | 2015-04-08 |
US20150051273A1 (en) | 2015-02-19 |
HK1206203A1 (zh) | 2016-01-08 |
CA2869057C (en) | 2019-07-09 |
CA2869057A1 (en) | 2013-10-03 |
JP6193970B2 (ja) | 2017-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104302183B (zh) | 飞燕草色素对抗金黄色葡萄球菌的应用 | |
Zhang et al. | Role of BP* C@ AgNPs in Bap-dependent multicellular behavior of clinically important methicillin-resistant Staphylococcus aureus (MRSA) biofilm adherence: a key virulence study | |
Ding et al. | Chitosan grafted with β-cyclodextrin: synthesis, characterization, antimicrobial activity, and role as absorbefacient and solubilizer | |
Wang et al. | Bacteria-responsive biopolymer-coated nanoparticles for biofilm penetration and eradication | |
Tyeb et al. | Agar–iodine transdermal patches for infected diabetic wounds | |
US20200129564A1 (en) | Compositions and methods for treating wounds | |
CN113713089A (zh) | 可消除伤口处生物膜的可溶解微针贴片及制备方法和应用 | |
CN107441494A (zh) | 一种抗菌膜活性的壳寡糖与抗生素及其应用 | |
Prasanna et al. | Medical biofilms–Its formation and prevention using organic molecules | |
EP2317998B1 (en) | Fulvic acid and antibiotic combination | |
DE2608079A1 (de) | Arzneipraeparat in form eines trockenpraeparats zur herstellung von injektionen | |
CN108403676B (zh) | 琥珀酸在提高细菌对抗生素敏感性方面的应用 | |
CN1850113A (zh) | 含有纳米银的阿莫西林抗菌剂及其制备方法、应用 | |
Fu et al. | Construction of pH-sensitive sodium alginates/sodium carboxymethyl cellulose/zeolite P composite hydrogel microspheres loaded with potassium diformate | |
CN109364259A (zh) | 一种载有利福平的复合外泌体及其制备方法 | |
Movaffagh et al. | The use of natural biopolymer of chitosan as biodegradable beads for local antibiotic delivery: release studies | |
Shi et al. | Research and Application of Chitosan Nanoparticles in Orthopedic Infections | |
CN1270723C (zh) | 一种阿奇霉素注射液及制备方法 | |
CN106798746A (zh) | 熊果酸新用途及含有熊果酸的组合物及其用途 | |
WO2024121651A1 (en) | A liquid herbal antibiotic and a powder herbal antibiotic containing a herbal antibacterial formulation | |
CN1301110C (zh) | 包含牛磺酰胺衍生物及羧酸和/或其盐的抗微生物闭锁 | |
Trukhachev et al. | Clinical and therapeutic efficacy of biodegradable nanostructures in experimental infections | |
CN108484793B (zh) | 一种菊粉-壳聚糖偶联物、药物组合物、其应用和其制备方法 | |
CN101780034B (zh) | 一种头孢硫脒混悬制剂及其应用 | |
CN100341887C (zh) | 门冬氨酸阿奇霉素及其制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1206203 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1206203 Country of ref document: HK |